Global Co-promotion and Co-marketing Partnering Deal Trends, by Phase of Development, Companies and Agreements Till 2019

Posted on 2019-04-03 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Apr-03 — /EPR Network/ —The market for Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech is growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2019” which offer details about the current trends and analysis, as well as scope for the near future. This research study also covers information about the production, consumption and market share based on different active regions. Furthermore, an anticipated growth at a double-digit CAGR for the Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech sector is highlighted in the report which indicates a prosperous future.

Get Sample Copy of this Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2222635

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the world’s leading biopharma companies.

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2014 to 2019.

For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms were available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of co-promotion and co-marketing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a review of the top 50 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2014.

In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.

Key benefits
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides the reader with the following key benefits:

In-depth understanding of co-promotion and co-marketing deal trends since 2014
Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
Comprehensive access to over 700 actual co-promotion and co-marketing deals entered into by the worlds biopharma companies
Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.

Request Report TOC @ https://www.marketresearchhub.com/report/global-co-promotion-and-co-marketing-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2014-2019-report.html

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in co-promotion and co-marketing deal making

2.1. Introduction

2.2. Difference between co-promotion and co-marketing deals

2.3. Trends in co-promotion deals since 2014

2.3.1. Co-promotion and co-marketing deal making by year, 2014 to 2019

2.3.2. Co-promotion and co-marketing deal making by phase of development, 2014 to 2019

2.3.3. Co-promotion and co-marketing deal making by industry sector, 2014 to 2019

2.3.4. Co-promotion and co-marketing deal making by therapy area, 2014 to 2019

2.3.5. Co-promotion and co-marketing deal making by technology type, 2014 to 2019

2.3.6. Co-promotion and co-marketing deal making by most active company, 2014 to 2019

2.4. When co-marketing can be useful

2.5. When co-marketing is the only option

2.6. Pure deals and multi-component deals

2.6.1. Attributes of pure co-promotion deals

2.6.2. Attributes of co-promotion in multi-component deals

2.7. Reasons for including co-promotion options in a deal

2.8. Uptake of co-promotion rights

2.9. Co-promotion rights as bargaining chips

2.10. Aligning partners to make the co-promote work

2.11. The future of co-promotion as part of multicomponent deals

Chapter 3 Overview of co-promotion deal structure

3.1. Introduction

3.2. Pure versus multi-component co-promotion deals

3.3. Pure co-promotion agreement structure

3.3.1. Example co-promotion agreements

3.3.1.a. Case study 1: Allergan MAP Pharmaceuticals

3.3.1.b. Case study 2: Genzyme Veracyte

3.4. Co-promotion rights as part of a wider alliance agreement

3.4.1. Example co-promotion option clauses

3.4.1.a. Case study 3: Takeda Pharmaceutical Orexigen Therapeutics

3.4.1.b. Case study 4: Celgene Acceleron Pharma

3.4.2. Example co-promotion right clauses

3.4.2.a. Case study 5: Takeda Orexigen

3.4.2.b. Case study 6: Abbvie Receptos

3.5. Embedded co-promotion rights enabling third party engagement

3.5.1. Example co-promotion clauses enabling third party engagement

3.5.1.a. Case study 7: Astellas Ambit Biosciences

Continued………. ##
Enquire About This Report @

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick